Gefitinib [184475-35-2]
Cat# HY-50895-100mg
Size : 100mg
Brand : MedChemExpress
Géfitinib (ZD1839) est un EGFR tyrosine kinase puissant, sélectif et actif par voie orale avec un IC50 de 33 nM. Géfitinib inhibe sélectivement la croissance des cellules tumorales stimulées par l'EGF (IC50 de 54 nM) et bloque l'autophosphorylation EGF-stimulée EGFR dans les cellules tumorales. Géfitinib induit également l'autophagie. Géfitinib a une activité antitumorale.
Gefitinib (ZD1839) ist ein potenter, selektiver und oral wirksamer EGFR tyrosine kinase-Inhibitor mit einem IC50 von 33 nM. Gefitinib hemmt selektiv das EGFR-stimulierte Wachstum von Tumorzellen (IC50 von 54 nM) und blockiert die b>EGFR-stimulierte EGFR-Autophosphorylierung in Tumorzellen. Gefitinib induziert auch autophagy. Gefitinib hat antitumorale Aktivität.
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
For research use only. We do not sell to patients.
Gefitinib Chemical Structure
CAS No. : 184475-35-2
This product is a controlled substance and not for sale in your territory.
Based on 134 publication(s) in Google Scholar
Other Forms of Gefitinib:
- Gefitinib hydrochloride In-stock
- Gefitinib-d8 In-stock
- Gefitinib-d6 In-stock
- Gefitinib-d3 In-stock
- Gefitinib dihydrochloride Get quote
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr 14. [Abstract]
- Gefitinib (0-20 μM; 24 h) significantly inhibits the viability of A549 cells.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. [Abstract]
- WT mice are either treated with vehicle or Gefitinib (100 mg/kg/day) starting one day prior to DEN injection (100 mg/kg). Livers are collected at 3 and 48 hr after DEN injection and subjected to IB analyses with the indicated antibodies.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]
- BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefitinib at 2.5 µM, SU 11248 at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269. [Abstract]
- WB is used to detect the effect of EGF treatment for 4 h on the expression of YAP with the inhibitors of EGFR or its downsream members, including Gefitinib, LY294002, Wortmannin, GSK2334470, BX-795, MK-2206, GSK1120212, and U0126 in the Si RhoA transfected HepG2 and SMMC7721 cells for 48 h in HepG2 and SMMC7721 cells.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Aug;37(31):4300-4312. [Abstract]
- Western blot analysis of E-cadherin and vimentin in HCC827 xenograft tumors treated with Gefitinib daily for 6-8 weeks until tumors regrown (resistant) or saline for 1 week (sensitive) (left panel).
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Oct;40(4):2242-2250. [Abstract]
- Effects of Gefitinib(G) and SC 58635 (Cel) on ABCB1 (MDR1), FOXM1 and Bcl 2 protein levels in PC3/DR and DU145/DR cell lines. The effects of Gefitinib, SC 58635 and their combination on ABCB1 (MDR1), FOXM1 and Bcl 2 expression in the PC3/DR and DU145/DR cell lines are determined by a western blot assay.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2017 Aug 4;19(1):90. [Abstract]
- The effect of Gefitinib-FTY720 treatment on CD44 expression in TNBC cell lines. HCC1806, Hs578T, and MDA-MB-468 TNBC cell lines at ~40% confluence in 12-well plates are exposed for 24 h to Gefitinib (Gef: 0.1 to 10 μM), with or without the addition of 1.5 μM FTY720.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2017 Dec 15;361(2):246-256. [Abstract]
- Western blot analysis for p21, p-p21, Cyclin D1. Bcl-2, Caspase 3, Cleaved Caspase 3, Caspase 9, Cleaved Caspase 9 and Bax in HCC827-GR and PC-9-GR cells treated with control, Efatutazone alone, Gefitinib alone, or Efatutazone combined with gefitinib for 48 h.
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2017 Sep;16(3):3475-3481. [Abstract]
- Cyclin B1 and Cdk1 protein expression levels are significantly downregulated in NCI-H1975 cells treated with the combination of DHA (5 µM) and Gefitinib (10 µM).
-
Gefitinib purchased from MedChemExpress. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775. [Abstract]
- Changes in Bcl-2 protein expression in MCF-7 cells after treatment with 2CdA, BMS-354825 or Gefitinib alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.